XSES
42T
Market cap66mUSD
Aug 04, Last price
0.09SGD
Name
Trendlines Group Ltd
Chart & Performance
P/E
—
P/S
11.64
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-50.52%
Rev. gr., 5y
0.87%
Revenues
6m
P
Net income
-34m
L-0.00%
CFO
-9m
L+39.30%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
The Trendlines Group Ltd. is a private equity and venture capital firm focused on commercializing innovative technologies. They specialize in early-stage investments, ranging from incubation and seed funding to start-up and even later-stage venture capital for more established companies. Their investment strategy targets high-growth sectors such as food, medical technology (medtech), clean technology, agrifood, agritechnology, and life sciences, specifically emphasizing medical devices, biotechnology, and pharmaceuticals. They also consider opportunities in security, general medical fields, and information technology. The firm primarily seeks to invest in companies located in Israel and Singapore. Beyond financial backing, Trendlines offers extensive support to entrepreneurs, encompassing business incubation, market strategy development, research and development guidance, commercialization services, business development, funding strategies, administrative assistance, and marketing communications. The preferred exit routes for their investments include mergers and acquisitions, public stock listings, or other strategic dispositions of holdings. To mitigate the risks inherent in developing new businesses, Trendlines leverages its own capital alongside government funding. The firm actively participates in all aspects of its portfolio companies, from technological innovation to comprehensive business construction. Founded in 1993, The Trendlines Group Ltd. is headquartered in M.P. Misgav, Israel, and maintains additional offices in Tel Aviv, Israel; Beijing, China; and Singapore.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||